Urokit Plus®

Potassium Citrate BP and Citric Acid Monohydrate BP Oral Solution

DESCRIPTION

Urokit Plus® is a combined preparation of Potassium Citrate & Citric Acid. Potassium Citrate is absorbed and metabolized to potassium bicarbonate, this acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the potassium citrate is excreted in the urine unchanged.

INDICATIONS

Urokit Plus® Oral Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting and tolerable, even when administered for long periods. Potassium Citrate does not neutralize the gastric juice or disturb digestion.

DOSAGE AND ADMINISTRATION

Urokit Plus® Oral Solution should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking. Proper dilution may help prevent gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.

To relieve discomfort in UTI:

Adults and children over 6 years: 10 mL 3 times daily, diluted with 1 glass of water Children 1-6 years: 5 mL 3 times daily, diluted with 1/2 glass of water

To prevent kidney stones, acidosis caused by kidney diseases, with uricosuric agent to prevent gout:

Adults: 10-15 mL 4 times daily; or as directed by the physician, diluted with 1 glass of water.

Pediatric: 5-10 mL 4 times daily; or as directed by the physician, diluted with 1/2 glass of water.

CONTRAINDICATIONS

Severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, and hyperkalemia from any cause. Known hypersensitivity to any ingredient.

SIDE EFFECTS

Urokit Plus® Oral Solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output.

WARNING AND PRECAUTION

Large doses may cause hyperkalemia an alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Do not exceed recommended dosage. Discontinue use if adverse reaction occurs.

Should be used with caution by patients with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, patients should be directed to dilute adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferable, to take each dose after meals to avoid saline laxative effect.

PHARMACEUTICAL PRECAUTION

Store at or below 30 °C temperature. Keep away from light and wet place. Keep out of the reach of children.

PACKAGING

Urokit Plus® Oral Solution : Bottle containing 200 mL of oral solution. Each 5 mL contains Potassium Citrate BP 1500 mg & Citric Acid

contains Potassium Citrate BP 1500 mg & Citric Ac Monohydrate BP 250 mg.

SK+F

Manufactured by

ESKAYEF PHARMACEUTICALS LTD.

TONGI, GAZIPUR, BANGLADESH ® REGD. TRADEMARK PM03501 V02